A defect notice has been issued for a blood pressure medication distributed in the UK after a packaging error led to an incorrect dose being printed on the label.
Packaging Error on Enalapril Maleate Tablets
Star Pharmaceuticals Limited made a typo on its packaging, resulting in the incorrect dose on the label. Its enalapril maleate 20 mg/hydrochlorothiazide 12.5 mg tablets incorrectly list the hydrochlorothiazide strength on the front of the carton as 12 mg instead of 12.5 mg, the Medicines and Healthcare products Regulatory Agency (MHRA) said.
The strength is, however, correct on all other faces of the carton, the leaflet, and the blister foil. Medicine containing hydrochlorothiazide is used to treat hypertension, as well as oedema associated with cardiac or hepatic disease and chronic heart failure.
Impact and Advice to Patients
It's estimated that 1,740 packs have been distributed in the UK with the error, and health professionals have been advised to reassure patients that the product itself is not affected. Patients should continue to take the medication as prescribed, as the tablets' quality is unaffected.
The MHRA notice said: "The risk associated with the labelling error is considered low because no corresponding strengths of the enalapril maleate/hydrochlorothiazide combination where the hydrochlorothiazide strength is expressed as 12 mg exist."
Patients with questions should seek advice from the healthcare professional involved in their treatment or from the pharmacy.
Earlier Recall of Lercanidipine Tablets
Earlier this month, a batch of Lercanidipine Hydrochloride 10mg tablets was recalled by Accord-UK Ltd after a packaging mistake resulted in tablets of the wrong strength being placed in some packs. The medication is widely prescribed across the UK to help control high blood pressure by relaxing and dilating blood vessels, making it easier for blood to flow throughout the body.
Hundreds of thousands of people rely on the treatment each year to manage the condition and reduce the risk of serious health problems such as heart attacks and strokes. A complaint submitted to the MHRA revealed that one affected pack contained a strip of the correct 10mg tablets alongside a strip of 20mg tablets, raising concerns that patients may receive the wrong dose.
Health officials warned that if someone prescribed a 10mg daily dose were to take 20mg tablets instead for a two-week period, they could experience an increased pharmacological effect from the medication. This may result in a greater-than-expected drop in blood pressure, potentially causing symptoms such as dizziness, headaches, flushing, heart palpitations and symptomatic hypotension.
The recall is currently being carried out at pharmacy and wholesaler level, as health officials have assessed the overall risk to patients as low. Authorities said this is because the 20mg tablets remain within the approved dosing range for the medication, the two strengths can be distinguished by their different colours, and reports of the packaging defect are believed to be extremely limited.